ANI Pharmaceuticals, Inc. (ANIP)

NASDAQ: ANIP · USD

$71.7

+0.50 (+0.7%)· Recorded snapshot

Market cap	1.5B
Revenue (ttm)	978.4M
Net income (ttm)	99.6M
EPS (ttm)	$4.54
Shares out	21.4M
P/E (trailing)	15.8x
P/E (forward)	7.8x
Volume	279,756
Beta	0.50

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 978.4M
Net income (ttm): 99.6M
EPS (ttm): $4.54
P/E (trailing): 15.8x
P/E (forward): 7.8x
Market cap: 1.5B

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	보유

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/E7.8

P25 n/aP50 n/aP75 n/a

Trailing P/E15.8

P25 n/aP50 n/aP75 n/a

ROE20.5

P25 n/aP50 n/aP75 n/a

ROIC11

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All ANIP indicators

Market & fundamental data

Available fields

262

Groups with data

Currency

USD

Showing 262 of 262 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001023024
Company name	ANI Pharmaceuticals, Inc.
Country	United States
Country code	US
CUSIP number	00182C103
Earnings date	2026-11-05
Earnings time	bmo
Employees	970
Employees change	73
Employees growth	8.14%
Enterprise value	$1.8B
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2001
In index	RUSSELL2000
Industry	Drug Manufacturers - Specialty & Generic
Is primary listing	Yes
Is SPAC	No
ISIN number	US00182C1036
Last 10-K release date	2026-02-27
Last earnings date	2026-08-07
Last refreshed	2026-10-28
Last stock split date	2013-07-18
Last stock split type	Reverse
Market cap	$1.5B
Market cap category	Small-Cap
Next earnings date	2026-11-05
Options	Yes
Price	$71.67
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	ANIP
U.S. state	Minnesota
Website	https://www.anipharmaceuticals.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Adjusted P/E ratio	8.3x
Average P/E ratio (3Y)	48.42x
Earnings yield	6.33%
EV/Earnings	18.02x
EV/EBIT	14.52x
EV/EBITDA	8.57x
EV/FCF	10.37x
EV/Sales	1.83x
FCF / EV yield	9.64%
FCF yield	11.19%
Forward EV/Sales	1.55x
Forward P/E	7.77x
Forward P/S	1.33x
Graham number	53.35174
Graham upside	-26.02%
Industry forward P/E	13.87x
Industry P/E	173.94x
P/(FCF - SBC) ratio	11.71x
P/(OCF - SBC) ratio	10.41x
P/B ratio	2.55x
P/E ratio	15.79x
P/FCF ratio	8.93x
P/OCF ratio	8.16x
P/S ratio	1.58x
PEG ratio	1.94x
Price / tangible book value	18.21x
Price/EBITDA ratio	7.38x
Sector forward P/E	23.56x
Sector P/E	50.08x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	12.63%
EBITDA margin	21.4%
Effective tax rate	24.04%
FCF margin	17.68%
Gross margin	60.4%
Operating margin	12.63%
Pretax margin	14.57%
Profit margin	11.07%
Profit per employee	$102,677
Profitable quarters	6
Profitable years	1
Revenue per employee	$1M
ROA	5.45%
ROA (5Y)	0.9%
ROCE	10.21%
ROE	20.46%
ROE (5Y)	-2.48%
ROIC	10.96%
ROIC (5Y)	2.07%
SBC / revenue	4.2%
Tax / revenue	3.5%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth (Q)	191.07%
EPS growth (QoQ)	-17.54%
EPS growth 10Y	18.22%
EPS growth quarters	5
EPS growth years	1
FCF growth	37.9%
FCF growth (Q)	-25.33%
FCF growth (QoQ)	2.51%
FCF growth 3Y	77.72%
FCF growth 5Y	84.53%
Gross profit growth	26.61%
Gross profit growth (Q)	21.3%
Gross profit growth 3Y	32.74%
Gross profit growth 5Y	37.03%
Net income growth (Q)	189.05%
Net income growth (QoQ)	-16.15%
Net income growth quarters	5
Net income growth years	1
OCF growth	36.17%
OCF growth (Q)	-25.25%
OCF growth (QoQ)	-2.92%
OCF growth 10Y	20.55%
OCF growth 3Y	66.2%
OCF growth 5Y	69.39%
Operating income growth	243.51%
Operating income growth (Q)	162.63%
Operating income growth 3Y	46.44%
Revenue growth	30.91%
Revenue growth (Q)	25.87%
Revenue growth (QoQ)	12.04%
Revenue growth 10Y	26.96%
Revenue growth 3Y	34.58%
Revenue growth 5Y	35.6%
Revenue growth quarters	19
Revenue growth years	14

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-16.5M
Depreciation and amortization	$85.8M
EBIT	$123.6M
EBITDA	$209.4M
EPS	$4.54
FCF per share	$8.07
Financing cash flow	$-24.6M
Free cash flow	$173M
Free cash flow minus SBC	$131.9M
Gross profit	$591M
Income taxes	$34.3M
Investing cash flow	$-21.9M
Net borrowing	$-14.2M
Net cash flow	$142.4M
Net income	$99.6M
Operating cash flow minus SBC	$148.4M
Operating income	$123.6M
Revenue	$978.4M
Stock-based compensation	$41.1M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	2.53
Book value per share	$27.87
Debt / EBITDA	2.93
Debt / equity	1.05
Debt / FCF	3.62
Goodwill	$62.5M
Interest coverage	4
Long-term assets	$668.7M
Long-term liabilities	$613.2M
Net cash (debt)	$-249.1M
Net cash / market cap	-16.12%
Net debt / EBITDA	1.19
Net debt / equity	0.42
Net debt / FCF	1.44
Piotroski F-Score	7
Property, plant and equipment	$73.2M
Shareholders' equity	$597.2M
Tangible book value	$84.9M
Tangible book value per share	$3.96
Total assets	$1.5B
Total cash	$377M
Total debt	$626M
Total liabilities	$896.9M
WACC	6.04%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.69
Current assets	$825.4M
Current liabilities	$283.7M
Current ratio	2.91
Inventory turnover	2.75
Net working capital	$186.1M
Quick ratio	2.3
Working capital	$541.8M
Working capital turnover	2.16

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-12.56%
Dividend yield	0%
Shareholder yield	-12.56%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y price change	9.62%
10Y return CAGR	0.92%
10Y total return	9.62%
150-day SMA	$77.63
1D price change	0.7%
1M price change	-2.58%
1M total return	-2.58%
1W price change	-0.8%
1W total return	-0.8%
1Y price change	-22.37%
1Y return CAGR	-22.38%
1Y total return	-22.37%
20-day SMA	$72.30
200-day SMA	$77.77
3M price change	-8.01%
3M total return	-8.01%
3Y price change	22.44%
3Y return CAGR	6.98%
3Y total return	22.44%
50-day SMA	$73.17
50-day SMA vs 200-day SMA	50under200
52-week high	$95.57
52-week high date	2025-11-05
52-week low	$69.58
52-week low date	2026-09-11
5Y price change	94.52%
5Y return CAGR	14.24%
5Y total return	94.52%
6M price change	-9.43%
6M total return	-9.43%
All-time high	$99.50
All-time high date	2025-09-10
All-time low	$4.80
All-time low date	2013-06-26
Average true range (ATR)	$2.03
Average volume	323.7K
Beta (1Y)	0.51
Beta (2Y)	0.47
Beta (5Y)	0.5
Change from 52-week high	-25.01%
Change from 52-week low	3%
Change from all-time high	-27.55%
Change from all-time low	1,401.56%
Change from open	0.56%
Day's gap	0.14%
Dollar volume	$20.1M
High price	$72.59
Low price	$70.31
Monthly RSI	49.83
Open price	$71.27
Position in 52-week range	59.65%
Premarket change	0.55%
Premarket close	$71.17
Premarket price	$71.56
Premarket volume	719
Previous close	$71.17
Price vs 150-day SMA	-7.14%
Price vs 20-day SMA	-0.28%
Price vs 200-day SMA	-7.3%
Price vs 50-day SMA	-1.47%
Relative volume	0.86
RSI	47.25
Sharpe ratio	-0.78
Sharpe ratio (3Y)	0.29
Sharpe ratio (5Y)	0.41
Sortino ratio	-0.92
Sortino ratio (3Y)	0.6
Sortino ratio (5Y)	0.83
Volume	279.8K
Weekly RSI	43.03
YTD price change	-8.68%
YTD total return	-8.68%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	19.7M
Float percentage	91.77%
Shares change (QoQ)	1.72%
Shares change (YoY)	12.56%
Shares held by insiders	6.15%
Shares held by institutions	114.98%
Shares outstanding	21.4M
Short % of float	17.65%
Short % of shares	16.2%
Short ratio	8.4 days

Deeper analysis on ANIP

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this ANIP report

Is a complete ANIP research report available?

No complete published report is available for ANI Pharmaceuticals, Inc. (ANIP) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

ANI Pharmaceuticals, Inc. (ANIP)

Price

Financial snapshot

Fair-value bridge

Latest news · ANIP

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All ANIP indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on ANIP

Frequently asked questions